LakeShore Reconciled Depreciation from 2010 to 2025

LSBPW Stock   0.06  0.00  0.000002%   
LakeShore Biopharma Reconciled Depreciation yearly trend continues to be fairly stable with very little volatility. Reconciled Depreciation will likely drop to about 37.9 M in 2025. During the period from 2010 to 2025, LakeShore Biopharma Reconciled Depreciation regression line of quarterly data had mean square error of 19.8 T and geometric mean of  30,950,560. View All Fundamentals
 
Reconciled Depreciation  
First Reported
2010-12-31
Previous Quarter
48.5 M
Current Value
37.9 M
Quarterly Volatility
6.4 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check LakeShore Biopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among LakeShore Biopharma's main balance sheet or income statement drivers, such as Depreciation And Amortization of 37.9 M, Interest Expense of 29.6 M or Selling General Administrative of 130.7 M, as well as many indicators such as Price To Sales Ratio of 10.68, Dividend Yield of 0.0 or PTB Ratio of 10.46. LakeShore financial statements analysis is a perfect complement when working with LakeShore Biopharma Valuation or Volatility modules.
  
Check out the analysis of LakeShore Biopharma Correlation against competitors.

Latest LakeShore Biopharma's Reconciled Depreciation Growth Pattern

Below is the plot of the Reconciled Depreciation of LakeShore Biopharma Co, over the last few years. It is LakeShore Biopharma's Reconciled Depreciation historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in LakeShore Biopharma's overall financial position and show how it may be relating to other accounts over time.
Reconciled Depreciation10 Years Trend
Slightly volatile
   Reconciled Depreciation   
       Timeline  

LakeShore Reconciled Depreciation Regression Statistics

Arithmetic Mean31,464,729
Geometric Mean30,950,560
Coefficient Of Variation20.34
Mean Deviation4,932,379
Median27,905,795
Standard Deviation6,398,467
Sample Variance40.9T
Range20.6M
R-Value0.74
Mean Square Error19.8T
R-Squared0.55
Significance0
Slope995,784
Total Sum of Squares614.1T

LakeShore Reconciled Depreciation History

202537.9 M
202448.5 M
202342.2 M
202236.7 M
202131.2 M

About LakeShore Biopharma Financial Statements

LakeShore Biopharma investors use historical fundamental indicators, such as LakeShore Biopharma's Reconciled Depreciation, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in LakeShore Biopharma. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Reconciled Depreciation48.5 M37.9 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for LakeShore Stock Analysis

When running LakeShore Biopharma's price analysis, check to measure LakeShore Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy LakeShore Biopharma is operating at the current time. Most of LakeShore Biopharma's value examination focuses on studying past and present price action to predict the probability of LakeShore Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move LakeShore Biopharma's price. Additionally, you may evaluate how the addition of LakeShore Biopharma to your portfolios can decrease your overall portfolio volatility.